EGFR-Mutated Advanced NSCLC: Enhancing Treatment Strategies and Patient Care With Novel Therapies
Panelists discuss how the evolving landscape of EGFR-mutated advanced non–small cell lung cancer (NSCLC) treatment, including novel therapies like amivantamab and subcutaneous administration, requires a focus on patient-centered care, shared decision-making, and multidisciplinary collaboration to improve outcomes and manage adverse effects effectively.
EP. 1: EGFR-Targeted Therapies in NSCLC: IV vs Subcutaneous Administration
December 23rd 2024Panelists discuss how amivantamab’s dual targeting of EGFR and MET may address resistance mechanisms and unmet needs in EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Dr Scott highlighting its potential clinical benefits, while Squires shares insights on managing the adverse event profile and strategies for managing adverse effects in patients receiving intravenous (IV) amivantamab.
EP. 2: Subcutaneous Amivantamab in Practice: Clinical Insights and AE Management
December 24th 2024Panelists discuss how the availability of subcutaneous amivantamab influences nursing approaches to patient care and education, with Squires sharing strategies for ensuring patients understand the new administration method and preparing them for treatment.
EP. 3: Clinical Decision-Making and Sequencing Strategies in EGFR-Mutated NSCLC
January 2nd 2025Panelists discuss how EGFR-targeted therapies differ in administration protocols and management strategies, with Palmer sharing tailored nursing interventions for oral tyrosine kinase inhibitors (TKIs) vs infusion or subcutaneous therapies, and Dr Scott addressing approaches to sequencing treatments, shared decision-making, and the role of resistance mechanisms and biopsy in guiding therapy decisions for EGFR-mutated advanced non–small cell lung cancer (NSCLC).
EP. 4: Patient-Centered Approaches in EGFR-Mutated NSCLC
January 6th 2025Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
